



Hundredth Legislature - First Session - 2007
Committee Statement
LB 247

Hearing Date: February 8, 2007
Committee On: Health and Human Services

Introducer(s): (Johnson)
Title: Change provisions relating to pharmaceuticals

Roll Call Vote – Final Committee Action:

- X Advanced to General File
 - Advanced to General File with Amendments
 - Indefinitely Postponed
-

Vote Results:

5	Yes	Senator(s): Johnson, Erdman, Hansen, Gay, Pankonin
	No	
	Present, not voting	
2	Absent	Senator(s): Howard, Stuthman

Proponents:
Senator Johnson
Bob Hallstrom

Representing:
Introducer
Nebraska Pharmacists Association

Opponents:

Representing:

Neutral:

Representing:

Summary of purpose and/or changes:

LB 247 makes technical changes to the Uniform Controlled Substances Act and the Pharmacy Practice Act.

The bill removes the term “compounding” from the definitions of “manufacture” in the Uniform Controlled Substances Act (UCSA) and “manufacturer” in the Wholesale Drug Distributor Licensing Act to conform them to the definitions used by the National Association of Boards of Pharmacy.

The bill adds language to the UCSA to exempt certain anabolic steroids from the list of Schedule II controlled substances that are exempted by the U.S. Drug Enforcement Administration list of exempt anabolic steroids, to conform state law to federal law.

The bill recognizes an exception for the drug “buprenorphine” to the prohibition against prescribing certain narcotic drugs for detoxification treatment or maintenance treatment of narcotic-dependent individuals.

The bill modifies the “verbal offer to counsel” that must be provided by a pharmacist to a patient or caregiver prior to dispensing or delivering a drug or device. The bill removes the requirement from the Pharmacy Practice Act that written information provided with dispensed prescription drugs must include all information found on the prescription label.

The bill changes provisions relating to the return of drugs to a pharmacy from a long-term care facility to provide that the term “long-care facility” does not include an assisted-living facility as otherwise defined under state law.

The bill clarifies “drug product selection” provisions, or the manner in which a practitioner may designate that “drug product selection” is not permitted for a particular drug or device.

Explanation of amendments, if any:

Senator Joel Johnson, Chairperson